Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D 3 (PRI-2191)

Steroids

Volumn 69, Issue 10, 2004, Pages 629-635

  Wietrzyk, Joanna ^a   Pełczyńska, Marzena ^a   Madej, Janusz ^b   Dzimira, Stanisław ^b   Kuśnierczyk, Halina ^a   Kutner, Andrzej ^c   Szelejewski, Wiesław ^c   Opolski, Adam ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^c INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

(1S,24R) 1,24 Dihydroxyvitamin D 3; Calcemic effect; Calcitriol; Combined antitumor treatment; LD 50; Toxicity

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CISPLATIN; CLODRONIC ACID; PRI 2191; TACALCITOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CALCIUM BLOOD LEVEL; CANCER MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INHIBITION; FEMALE; HYPERCALCEMIA; LD 50; MALE; MOUSE; NONHUMAN; SPECIES COMPARISON; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CALCINOSIS; CALCITRIOL; CALCIUM; CISPLATIN; CLODRONIC ACID; DIHYDROXYCHOLECALCIFEROLS; DRUG THERAPY, COMBINATION; FEMALE; LETHAL DOSE 50; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA;

ANIMALIA;

EID: 4644321552     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2004.05.015     Document Type: Conference Paper

References (57)

1. A. Opolski, J. Wietrzyk, A. Chrobak, E. Marcinkowska, E. Wojdat, and A. Kutner Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines Anticancer Res 19 1999 5217 5222
2. H. Asou, M. Koike, E. Elstner, M. Cambell, J. Le, and M.R. Uskokovic 19-Nor vitamin-D analogues: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukaemia cell lines Blood 92 1998 2441 2449
3. 3 and retinoic acid Exp Cell Res 249 1999 2279 2290
4. 3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene Anticancer Drugs 2 1991 475 480
5. 3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RARα mediates the antiangiogenic effect of retinoids Cancer Lett 89 1995 117 124
6. A.W. Norman, M.T. Mizwicki, and W.H. Okamura Ligand structure-function relationships in the vitamin D endocrine system from the perspective of drug development (including cancer treatment) J. Reichrath M. Friedrich W. Tilgen Vitamin D analogs in cancer prevention and therapy 2003 Springer Verlag Berlin, Heidelberg 55 82
7. A. Opolski, J. Wietrzyk, A. Siwinska, E. Marcinkowska, A. Chrobak, and C. Radzikowski Biological activity in vitro of side-chain modified analogues of calcitriol Curr Pharm Des 6 2000 755 765
8. E. Marcinkowska, A. Kutner, and C. Radzikowski Cell differentiating and anti-proliferative activity of side-chain modified analogues of 1,25-dihydroxyvitamin D3 J Steroid Biochem Mol Biol 67 1998 71 78
9. Y. Ji, A. Kutner, A. Verstuyf, L. Verlinden, and G.P. Studzinski Derivatives of vitamins D2 and D3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells Cell Cycle 1 2002 410 415
10. E. Marcinkowska, and A. Kutner Side-chain modified vitamin D analogs require activation of both PI 3-K and erk1, 2 signal transduction pathways to induce differentiation of human promyelocytic leukemia cells Acta Biochim Pol 49 2002 393 406
11. M.R. Shokravi, D.M. Marcus, J. Alroy, K. Egan, M.A. Saornil, and D.M. Albert Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma Invest Ophthalmol Vis Sci 36 1995 83 87
12. 3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence Cancer Immunol Immunother 41 1995 37 45
13. S.A. Lamprecht, and M. Lipkin Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms Nat Rev Cancer 3 2003 601 614
14. J. Welsh, J.A. Wietzke, G.M. Zinser, B. Byrne, K. Smith, and C.J. Narvaez Vitamin D-3 receptor as a target for breast cancer prevention J Nutr 133 7 Suppl 2003 2425S 2433S
15. R.G. Mehta, E.A. Hussain, R.R. Mehta, and T.K. Das Gupta Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D Mutat Res 523/524 2003 253 264
16. A.V. Krishnan, D.M. Peehl, and D. Feldman The role of vitamin D in prostate cancer Recent Results Cancer Res 164 2003 205 221
17. D.C. Smith, C.S. Johanson, C.C. Freeman, J. Muindi, J.W. Wilson, and D.L. Trump A phase I trial of calcitriol (1,25-dihydroxycalciferol) in patients with advanced malignancy Clin Cancer Res 5 1999 1339 1345
18. D.M. Peehl, A.V. Krishnan, and D. Feldman Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer J Nutr 133 7 Suppl 2003 2461S 2469S
19. K. Dalhoff, J. Dancey, L. Astrup, T. Skovsgaard, K.J. Hamberg, and F.J. Lofts A phase II study of the vitamin D analogue seocalcitol in patients with inoperable hepatocellular carcinoma Br J Cancer 89 2003 252 257
20. J.R. Muindi, Y. Peng, D.M. Potter, P.A. Hershberger, J.S. Tauch, and M.J. Capozzoli Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel Clin Pharmacol Ther 72 2002 648 659
21. T.M. Beer, K.M. Hough, M. Garzotto, B.A. Lowe, and W.D. Henner Weekly high-dose calcitriol and docetaxel in advanced prostate cancer Semin Oncol 28 4 Suppl 15 2001 49 55
22. 3 and platinum drugs on the growth of MCF-7 cells Cancer Res 51 1991 2848 2853
23. 3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage Cancer Res 59 1999 862 867
24. A. Siwinska, A. Opolski, A. Chrobak, J. Wietrzyk, E. Wojdat, and A. Kutner Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D Anticancer Res 21 2001 1925 1929
25. R. Bouillon, W.H. Okamura, and A.W. Norman Structure-function relationship in the vitamin D endocrine system Endocr Rev 16 1995 200 257
26. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia Endocrinology 129 1991 832 837
27. J. Abe-Hashimoto, T. Kikuchi, T. Matsumoto, Y. Nishii, E. Ogata, and K. Ikeda Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen Cancer Res 53 1993 2534 2537
28. T.M. Beer, D. Lemmon, B.A. Lowe, and W.D. Henner High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma Cancer 97 2003 1217 1224
29. D.L. Hartenbower, T.M. Stanley, J.W. Coburn, and A.W. Norman Serum and renal histologic changes in the rat following administration of toxic amounts of 1,25-dihydroxyvitamin D3 A.W. Norman K. Schaefer J.W. Coburn H.F. De Luca D. Fraser H.G. Grigoleit D. van Herrath Vitamin D: biochemical, chemical and clinical aspects related to calcium metabolism 1977 Walter de Gruyter Berlin, New York 587 589
30. R. Bouillon, W.H. Okamura, and A.W. Norman Structure-function relationship in the vitamin D endocrine system Endocr Rev 16 1995 200 257
31. S. Majewski, A. Kutner, and S. Jablonska Vitamin D analogs in cutaneous malignancies Curr Pharm Des 6 2000 829 838
32. H. Sato, I. Sugimoto, T. Matsunaga, M. Tsuchimoto, T. Ohta, and H. Uno (1,24(OH)2D3, TV-02) inhibits phorbol ester-induced epidermal proliferation and cutaneous inflammation, and induces epidermal differentiation in mice Arch Dermatol Res 288 1996 656 663
33. T. Kobayashi, H. Okumura, Y. Azuma, M. Kiyoki, K. Matsumoto, and K. Hashimoto 1 Alpha,24R-dihydroxyvitamin D3 has an ability comparable to that of 1 alpha, 25-dihydroxyvitamin D3 to induce keratinocyte differentiation J Dermatol 17 1990 707 709
34. K. Matsumoto, K. Hashimoto, M. Kiyoki, M. Yamamoto, and K. Yoshikawa Effect of 1, 24R-dihydroxyvitamin D3 on the growth of human keratinocytes J Dermatol 17 1990 97 103
35. T. Matsunaga, M. Yamamoto, H. Mimura, T. Ohta, M. Kiyoki, and T. Ohba 1,24(R)-Dihydroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity J Dermatol 17 1990 135 142
36. H. Takahashi, M. Ibe, M. Kinouchi, A. Ishida-Yamamoto, Y. Hashimoto, and H. Iizuka Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation J Dermatol Sci 31 1 2003 21 28
37. H. Gollnick, and T. Menke Current experience with tacalcitol ointment in the treatment of psoriasis Curr Med Res Opin 14 1998 213 218
38. N.K. Veien, J.R. Bjerke, I. Rossmann-Ringdahl, and H.B. Jakobsen Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial Br J Dermatol 137 1997 581 586
39. D.C. Peters, and J.A. Balfour Tacalcitol. Drugs 54 1997 265 271
40. F.A. Castelijns, M.J. Gerritsen, I.M. van Vlijmen-Willems, P.J. van Erp, and P.C. van de Kerkhof Proliferation is the main epidermal target in the treatment of psoriatic plaques with once daily application of tacalcitol ointment Acta Derm Venereol 79 1999 111 114
41. M. Chodyński, J. Wietrzyk, E. Marcinkowska, A. Opolski, W. Szelejewski, and A. Kutner Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D(2). (24E)-(1S)-24-Dehydro-24a-homo-1,25-dihydroxyergocalciferol and congeners Steroids 67 2002 789 798
42. Kutner A, Chodyński M, Szelejewski W, Odrzywolska M, Fitak H. Polish patent application no. P-324274. CA131:102429.1998.
43. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 2002 584 593
44. P.A. Price, J.R. Buckley, and M.K. Williamson The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats J Nutr 131 2001 2910 2915
45. K.W. Colston, G. Pirianov, E. Bramm, K.J. Hamberg, and L. Binderup Effects of seocalcitol (EB1089) on nitrosomethyl urea-induced rat mammary tumors Breast Cancer Res Treat 80 2003 303 311
46. R.H. de Jong Generalized analysis of quantal dose-response curves Comput Biomed Res 6 1973 588 595
47. D.R. Waud On biological assays involving quantal responses J Pharmacol Exp Ther 183 1972 577 607
48. R.J. Tallarida, and Murray RB Procedure 46. Litchfield and Wilcoxon I: confidence limits of ED50, and Procedure 47. Litchfield and Wilcoxon II Manual of pharmacologic calculations, with computer programs 1987 Springer-Verlag New York, Berlin, Heidelberg 153 163
49. L. Verlinden, A. Verstuyf, M. Van Camp, S. Marcelis, K. Sabbe, and X.Y. Zhao Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo Cancer Res 60 2000 2673 2679
50. T. Kumagai, J. O'Kelly, J.W. Said, and H.P. Koeffler Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells J Natl Cancer Inst 95 2003 896 905
51. G.H. Posner, K.R. Crawford, S. Peleg, J.E. Welsh, S. Romu, and D.A. Gewirtz A non-calcemic sulfone version of the vitamin D(3) analogue seocalcitol (EB 1089): chemical synthesis, biological evaluation and potency enhancement of the anticancer drug adriamycin Bioorg Med Chem 9 2001 2365 2371
52. J.Y. Zhou, A.W. Norman, M. Akashi, D.L. Chen, M.R. Uskokovic, and J.M. Aurrecoechea Development of a novel 1,25(OH)2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism Blood 78 1991 75 82
53. M.J. Campbell, G.S. Reddy, and H.P. Koeffler Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects J Cell Biochem 66 1997 413 425
54. S.J. Sabet, S.R. Darjatmoko, M.J. Lindstrom, and D.M. Albert Antineoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 in athymic mice with Y-79 human retinoblastoma tumors Arch Ophthalmol 117 1999 365 370
55. P.A. Hershberger, W.D. Yu, R.A. Modzelewski, R.M. Rueger, C.S. Johnson, and D.L. Trump Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis Clin Cancer Res 7 2001 1043 1051
56. K.A. Moffatt, W.U. Johannes, and G.J. Miller 1Alpha, 25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines Clin Cancer Res 5 1999 695 703
57. M. Mazurkiewicz, A. Opolski, J. Wietrzyk, C. Radzikowski, and Z. Kleinrok GABA level and GAD activity in human and mouse normal and neoplastic mammary gland J Exp Clin Cancer Res 18 1999 247 253